Intuitive Surgical, US46120E6023

Intuitive Surgical stock holds near $400 after Oppenheimer upgrade

Published on 08/14/2026 at 07:35 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Intuitive Surgical stock trades at $399.87 after an Oppenheimer upgrade to Outperform on August 12, 2026, while Q2 2026 revenue and procedure growth stayed ahead of estimates.

Architekturaufnahme eines modernen Technologiecampus in Nordkalifornien mit Glas-Stahl-Gebäuden, Palmen, geometrischen Innenhöfen und goldener Abendsonne, die sich in den Glasfassaden spiegelt
Intuitive Surgical US46120E6023 generischer Silicon Valley Technologiecampus im goldenen Abendlicht mit gläsernen Fassaden, Illustration mit AI erstellt.

Intuitive Surgical stock (ISIN US46120E6023) trades at $399.87 as of August 14, 2026, with a 52-week range of $328.57 to $603.88 and intraday market value of $143.261 billion. The move comes after a quote page showed the shares down 0.35% in early trading and an analyst upgrade landed on August 12, 2026.

Upgrade meets a stretched valuation

The same quote page showed a trailing P/E of 45.91 and forward P/E of 36.50, while revenue on a trailing basis stood at $11.03 billion and net income at $3.14 billion. That mix leaves the stock priced for continued growth even after a strong second quarter.

Analyst sentiment is still positive, with a 1y target estimate of $477.25 and a reported price-target high of $685.00 versus a low of $324.00. The gap between the current quote and the consensus target underscores how much of the growth story is already in the share price.

Q2 still sets the tone

Yahoo Finance’s company overview said Intuitive Surgical reported a strong Q2 2026 earnings beat, with revenue vs. earnings charts showing $2.89 billion in revenue and $818.1 million in earnings for Q2 FY26. The same page noted that management raised 2026 guidance and that 468 da Vinci system placements supported the quarter.

That matters because the stock’s latest rerating is tied less to one day’s tape and more to whether procedure growth can keep matching the company’s premium multiple. For investors, the key number is the spread between the current P/E of 45.91 and the forward P/E of 36.50.

Da Vinci remains the anchor

Intuitive Surgical’s da Vinci surgical system remains the core product, and the company’s platform also includes Ion and related instruments, accessories, and service offerings. The business model still depends on installed systems, procedure volumes, and recurring consumables tied to those procedures.

Price and market view

Shares were last shown at $399.87, with a market cap of $143.261 billion, on August 14, 2026. The stock is still trading well below its 52-week high of $603.88.

Fact box

Company: Intuitive Surgical, Inc.
ISIN: US46120E6023
Ticker: ISRG
Exchange: NasdaqGS - Nasdaq Real Time Price
Sector / Industry: Healthcare / Medical Instruments & Supplies
Price (as of August 14, 2026, 9:33 a.m. ET): $399.87 USD
Market cap: $143.261 billion (as of August 14, 2026)
Next earnings date: October 20, 2026

Disclaimer...

en | US46120E6023 | INTUITIVE SURGICAL | boerse | 69947833 | bgmi